218 related articles for article (PubMed ID: 33314769)
1. PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma.
Scheinberg T; Lomax A; Tattersall M; Thomas D; McCowage G; Sullivan M; Karim R; Luk PP; Mahar A; Bonar F; Bhadri VA
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1327. PubMed ID: 33314769
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
3. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
4. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
5. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
6. Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D; Liebner DA; Philippon JS; Hoffman S; Tan Y; Chen JL; Lenobel S; Wakely PE; Pollock R; Tinoco G
BMC Cancer; 2020 Jun; 20(1):527. PubMed ID: 32503455
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
Assi T; Cesne AL; Mir O
Immunotherapy; 2021 Feb; 13(2):91-93. PubMed ID: 33291976
[No Abstract] [Full Text] [Related]
8. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
9. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study.
Liu Z; Liu C; Yao W; Gao S; Wang J; Zhang P; Ge H
Anticancer Drugs; 2021 Oct; 32(9):962-968. PubMed ID: 34001702
[TBL] [Abstract][Full Text] [Related]
11. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
ElNaggar AC; Hays JL; Chen JL
PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
13. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
14. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
15. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.
Reichardt P; Pink D; Tilgner J; Kretzschmar A; Thuss-Patience PC; Dörken B
Onkologie; 2002 Dec; 25(6):541-6. PubMed ID: 12566899
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
18. ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children.
Aydin B; Akyuz C; Varan A; Yalcin B; Kurucu N; Kutluk T
Rev Recent Clin Trials; 2018; 13(2):126-131. PubMed ID: 29366426
[TBL] [Abstract][Full Text] [Related]
19. Rapid and Complete Response to Combination Anti-CTLA-4 and Anti-PD-1 Checkpoint Inhibitor Therapy in a Patient With Stage IV Refractory End-stage Epithelioid Sarcoma: A Case Report.
Pecora A; Halpern S; Weber M; Paleoudis EG; Panush D; Patterson F; Toretsky J
J Immunother; 2020; 43(9):286-290. PubMed ID: 32815894
[TBL] [Abstract][Full Text] [Related]
20. Early outcomes of soft tissue sarcomas presenting with metastases and treated with chemotherapy.
King JJ; Fayssoux RS; Lackman RD; Ogilvie CM
Am J Clin Oncol; 2009 Jun; 32(3):308-13. PubMed ID: 19433963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
